In summary, the preclinical pharmacology data indicate CUSP06 has promising therapeutic potential in treating CDH6-expressing malignant solid tumors including ovarian, renal, uterine cancer and cholangiocarcinoma, and in tumors that are CDH6-low, as well as CDH6-high. Here, CDH6 is linked to cholangiocarcinoma.